BIO Europe Spring in Lisbon

A great couple of days at hashtag#BIOEuropeSpring, with plenty of valuable conversations across the biotech and pharma space.

The current high level of activity around partnering and collaboration was evident at the conference; with 3 days filled with rapid-fire meetings between pharma, biotech and service providers.

Our CEO, Jan Thirkettle was there on behalf of Harness Therapeutics, meeting with potential partners and collaborators as well as catching up with the latest insights and news in the neuroscience deal-making space.

hashtag#BIOEuropeSpring hashtag#LifeSciences hashtag#BiotechInnovation hashtag#Pharma hashtag#Partnerships hashtag#HealthcareInnovation hashtag#Networking hashtag#HarnessTx

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

View all